Skip to main content
. 2015 Aug 25;10(1):101–112. doi: 10.1016/j.molonc.2015.08.004

Figure 2.

Figure 2

mTOR/DDR signalling pathway changes. HT29 cells were treated with 0.1 μM of the mTOR inhibitors AZD8055, RAD‐001, rapamycin or BEZ235, or gemcitabine in combination with 0 or 0.4 μM of the Chk1 inhibitor V158411 for 48 h. Expression levels of proteins involved in mTOR signalling (A) or DNA damage signalling (B) were determined by immunoblotting.